← All trials
NCT05680454
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2019
- Primary completion
- Apr 6, 2020
- Completion date
- May 10, 2022
- First posted
- Jan 11, 2023
- Last posted
- Jan 17, 2023
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing Health Guard Biotechnology, IncLead sponsor
- Beijing Health Guard Biotechnology, IncStudy chair
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Beijing Health Guard Biotechnology, IncOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.